NUCALA Trademark

Trademark Overview

On Thursday, July 14, 2011, a trademark application was filed for NUCALA with the United States Patent and Trademark Office. The USPTO has given the NUCALA trademark a serial number of 85371627. The federal status of this trademark filing is REGISTERED AND RENEWED as of Tuesday, August 27, 2024. This trademark is owned by Glaxo Group Limited. The NUCALA trademark is filed in the Pharmaceutical Products category with the following description:

[ Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines(Based on 44(d) Priority Application) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; ] Pharmaceutical preparations and substances for the treatment of [ viral, me...
nucala

General Information

Serial Number85371627
Word MarkNUCALA
Filing DateThursday, July 14, 2011
Status800 - REGISTERED AND RENEWED
Status DateTuesday, August 27, 2024
Registration Number4714559
Registration DateTuesday, April 7, 2015
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 20, 2015

Trademark Statements

Goods and Services[ Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines(Based on 44(d) Priority Application) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; ] Pharmaceutical preparations and substances for the treatment of [ viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, ] respiratory, [ neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related ] diseases and disorders [ ; Vaccines ]

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, July 19, 2011
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGlaxo Group Limited
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressStevenage SG12NY
GB
Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBrentford, Middlesex TW89GS
GB
Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressGreenford, Middlesex UB60NN
GB

Trademark Events

Event DateEvent Description
Friday, November 4, 2011APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, July 18, 2011NEW APPLICATION ENTERED
Tuesday, July 19, 2011NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, November 3, 2011ASSIGNED TO EXAMINER
Friday, November 11, 2011ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Monday, November 14, 2011ELECTRONIC RECORD REVIEW COMPLETE
Wednesday, November 30, 2011NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 20, 2011PUBLISHED FOR OPPOSITION
Tuesday, December 20, 2011OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 14, 2012NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, August 2, 2012SOU TEAS EXTENSION RECEIVED
Thursday, August 2, 2012SOU EXTENSION 1 FILED
Thursday, August 2, 2012SOU EXTENSION 1 GRANTED
Saturday, August 4, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 30, 2013SOU TEAS EXTENSION RECEIVED
Wednesday, January 30, 2013SOU EXTENSION 2 FILED
Tuesday, February 12, 2013CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, February 12, 2013SOU EXTENSION 2 GRANTED
Wednesday, February 13, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 15, 2013TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, March 15, 2013ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, March 25, 2013TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, March 25, 2013APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 7, 2013SOU TEAS EXTENSION RECEIVED
Wednesday, August 7, 2013SOU EXTENSION 3 FILED
Friday, August 16, 2013SOU EXTENSION 3 GRANTED
Saturday, August 17, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 3, 2014SOU TEAS EXTENSION RECEIVED
Friday, January 3, 2014SOU EXTENSION 4 FILED
Monday, January 13, 2014SOU EXTENSION 4 GRANTED
Tuesday, January 14, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 19, 2014SOU TEAS EXTENSION RECEIVED
Thursday, June 19, 2014SOU EXTENSION 5 FILED
Saturday, June 21, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, June 20, 2014SOU EXTENSION 5 GRANTED
Thursday, December 4, 2014TEAS PETITION TO AMEND BASIS RECEIVED
Tuesday, December 16, 2014ASSIGNED TO PETITION STAFF
Tuesday, December 16, 2014PETITION TO DIRECTOR GRANTED
Wednesday, December 17, 2014NOTICE OF ALLOWANCE CANCELLED
Wednesday, December 31, 2014NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 20, 2015PUBLISHED FOR OPPOSITION
Tuesday, January 20, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 7, 2015REGISTERED-PRINCIPAL REGISTER
Tuesday, April 7, 2020COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Monday, February 8, 2021TEAS SECTION 8 & 15 RECEIVED
Tuesday, June 15, 2021CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Tuesday, June 15, 2021REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Tuesday, June 15, 2021NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Tuesday, November 8, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, November 8, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, November 8, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, July 5, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, July 5, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, July 5, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, July 5, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, July 5, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, June 13, 2024TEAS SECTION 8 & 9 RECEIVED
Tuesday, August 27, 2024CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Tuesday, August 27, 2024REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Tuesday, August 27, 2024REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Tuesday, August 27, 2024NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Sunday, April 7, 2024COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED

Related Keywords

nucala pharmaceutical substances treatment preparations disorders diseases sepsis viral inflammation cognitive